A prospective observational study of Active surveillance in primary desmoid fibromatosis

医学 危险系数 比例危险模型 内科学 临床终点 纤维瘤病 前瞻性队列研究 侵袭性纤维瘤病 观察研究 原发性肿瘤 无进展生存期 外科
作者
Chiara Colombo,Marco Fiore,Giovanni Grignani,Francesco Tolomeo,Alessandra Merlini,Elena Palassini,Paola Collini,Silvia Stacchiotti,Paolo G. Casali,Federica Perrone,Luigi Mariani,Ugo Pastorino
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
标识
DOI:10.1158/1078-0432.ccr-21-4205
摘要

To prospectively assess the behaviour of primary sporadic (not FAP associated) desmoid fibromatosis (DF) managed by active surveillance (AS).This is an Italian prospective, multicenter, observational study (NCT02547831) including patients {greater than or equal to}16 years with primary sporadic DF at any site. Patients were assessed by Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 . Primary end-point was progression-free survival (PFS) at 3 years. Treatment-free survival (TFS) was also analyzed. PFS and TFS were calculated by Kaplan-Meier plots and compared by log-rank test Cox proportional-hazard multivariable regression analyses were performed.From 2013 to 2018 108 consecutive patients were included (82% female); median age was 39-yr; median size was 51 mm. CTNNB1 mutations were: T41A (50%); S45F (12%); other (19%); WT (19%). At 32.3-month median-FU, 42/108 (39%) showed RECIST progression. Spontaneous regression (SR) was initially observed in 27/108 (25%), while it followed dimensional progression in other 33/108 (31%). PFS at 36 months was 54.5% (95% CI, 44.9%-66.1%). Thirty-five/108 (32%) patients received active treatments, 18/108 (17%) after RECIST progression and 17/108 (15%) after symptomatic progression. TFS at 36 months was 65.9% (95% CI, 57.3%-75.9%). Larger tumor size and extremity location were associated to shorter TFS and a trend for S45F mutation was also observed (p=0.06), while none of the above variables was significantly associated to PFS.In primary DF, AS can be proposed, since disease stabilization and SR frequently occur. However extra care should be taken for patients with tumors of larger size, extremity location and S45F mutation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
ding应助Eunice采纳,获得10
刚刚
情怀应助htt采纳,获得10
刚刚
科研通AI6.2应助fms采纳,获得10
刚刚
yyy发布了新的文献求助10
1秒前
呵呵呵应助kevin采纳,获得30
1秒前
1秒前
张嘉雯发布了新的文献求助10
1秒前
1秒前
haaaaaa发布了新的文献求助10
1秒前
1秒前
2秒前
2秒前
2秒前
阔达的琦完成签到 ,获得积分10
2秒前
2秒前
夏初序完成签到,获得积分20
3秒前
LXZ发布了新的文献求助10
3秒前
3秒前
3秒前
自然雁风发布了新的文献求助10
3秒前
XY发布了新的文献求助10
3秒前
ZhangChulun发布了新的文献求助10
3秒前
4秒前
完美世界应助深深采纳,获得10
4秒前
拉长的鞋垫完成签到 ,获得积分10
4秒前
SciGPT应助鹰击长空采纳,获得10
4秒前
4秒前
5秒前
无限半芹完成签到,获得积分10
5秒前
佳佳完成签到,获得积分10
5秒前
xhuryts发布了新的文献求助10
5秒前
夏初序发布了新的文献求助10
6秒前
mort发布了新的文献求助10
6秒前
123完成签到,获得积分10
6秒前
戒骄戒躁完成签到,获得积分20
6秒前
6秒前
科研通AI6.4应助liulanglang采纳,获得10
6秒前
科研小白发布了新的文献求助10
6秒前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
48V Low-voltage Power Distribution Network (PDN) Architecture Industry Report, 2024 800
ズームレンズの光学設計に関する研究 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
Matrix Methods in Data Mining and Pattern Recognition Second Edition 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7300932
求助须知:如何正确求助?哪些是违规求助? 8919246
关于积分的说明 18890711
捐赠科研通 6965678
什么是DOI,文献DOI怎么找? 3211286
关于科研通互助平台的介绍 2380363
邀请新用户注册赠送积分活动 2188058